Michael Heneka to Interleukin-1beta
This is a "connection" page, showing publications Michael Heneka has written about Interleukin-1beta.
Connection Strength
0.872
-
Braatz C, Komes MP, Ravichandran KA, de Fragas MG, Griep A, Schwartz S, McManus RM, Heneka MT. NLRP3-directed antisense oligonucleotides reduce microglial immunoactivities in vitro. J Neurochem. 2024 Oct; 168(10):3467-3481.
Score: 0.184
-
Jiang S, Maphis NM, Binder J, Chisholm D, Weston L, Duran W, Peterson C, Zimmerman A, Mandell MA, Jett SD, Bigio E, Geula C, Mellios N, Weick JP, Rosenberg GA, Latz E, Heneka MT, Bhaskar K. Proteopathic tau primes and activates interleukin-1? via myeloid-cell-specific MyD88- and NLRP3-ASC-inflammasome pathway. Cell Rep. 2021 09 21; 36(12):109720.
Score: 0.166
-
Friker LL, Scheiblich H, Hochheiser IV, Brinkschulte R, Riedel D, Latz E, Geyer M, Heneka MT. ?-Amyloid Clustering around ASC Fibrils Boosts Its Toxicity in Microglia. Cell Rep. 2020 03 17; 30(11):3743-3754.e6.
Score: 0.150
-
Scheiblich H, Schl?tter A, Golenbock DT, Latz E, Martinez-Martinez P, Heneka MT. Activation of the NLRP3 inflammasome in microglia: the role of ceramide. J Neurochem. 2017 12; 143(5):534-550.
Score: 0.127
-
Heneka MT. Inflammasome activation and innate immunity in Alzheimer's disease. Brain Pathol. 2017 03; 27(2):220-222.
Score: 0.121
-
Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, Gelpi E, Halle A, Korte M, Latz E, Golenbock DT. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013 Jan 31; 493(7434):674-8.
Score: 0.091
-
Tzeng TC, Hasegawa Y, Iguchi R, Cheung A, Caffrey DR, Thatcher EJ, Mao W, Germain G, Tamburro ND, Okabe S, Heneka MT, Latz E, Futai K, Golenbock DT. Inflammasome-derived cytokine IL18 suppresses amyloid-induced seizures in Alzheimer-prone mice. Proc Natl Acad Sci U S A. 2018 09 04; 115(36):9002-9007.
Score: 0.034